Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 15 November

Grady Wulff
November 15, 2023

Morning Bell 14 November

Sam Kanaan
November 14, 2023

Morning Bell 13 November

Sophia Mavridis
November 13, 2023

Weekly Wrap 10 November

Sophia Mavridis
November 10, 2023

Morning Bell 10 November

Sam Kanaan
November 10, 2023

Morning Bell 9 November

Sophia Mavridis
November 9, 2023

Morning Bell 8 November

Sam Kanaan
November 8, 2023

Morning Bell 7 November

Sophia Mavridis
November 7, 2023

Morning Bell 6 November

Sam Kanaan
November 6, 2023

Weekly Wrap 3 November

Grady Wulff
November 3, 2023

Morning Bell 3 November

Sam Kanaan
November 3, 2023

Morning Bell 2 November

Grady Wulff
November 2, 2023